1. Home
  2. ADVM vs FAAS Comparison

ADVM vs FAAS Comparison

Compare ADVM & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • FAAS
  • Stock Information
  • Founded
  • ADVM 2006
  • FAAS 2021
  • Country
  • ADVM United States
  • FAAS Indonesia
  • Employees
  • ADVM N/A
  • FAAS N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • FAAS
  • Sector
  • ADVM Health Care
  • FAAS
  • Exchange
  • ADVM Nasdaq
  • FAAS NYSE
  • Market Cap
  • ADVM 47.4M
  • FAAS 48.2M
  • IPO Year
  • ADVM 2014
  • FAAS N/A
  • Fundamental
  • Price
  • ADVM $2.17
  • FAAS $0.59
  • Analyst Decision
  • ADVM Strong Buy
  • FAAS
  • Analyst Count
  • ADVM 5
  • FAAS 0
  • Target Price
  • ADVM $23.80
  • FAAS N/A
  • AVG Volume (30 Days)
  • ADVM 339.0K
  • FAAS 8.7M
  • Earning Date
  • ADVM 08-11-2025
  • FAAS 01-01-0001
  • Dividend Yield
  • ADVM N/A
  • FAAS N/A
  • EPS Growth
  • ADVM N/A
  • FAAS N/A
  • EPS
  • ADVM N/A
  • FAAS N/A
  • Revenue
  • ADVM $1,000,000.00
  • FAAS $57,730,593.00
  • Revenue This Year
  • ADVM N/A
  • FAAS N/A
  • Revenue Next Year
  • ADVM $18.82
  • FAAS N/A
  • P/E Ratio
  • ADVM N/A
  • FAAS N/A
  • Revenue Growth
  • ADVM N/A
  • FAAS 38.16
  • 52 Week Low
  • ADVM $1.78
  • FAAS $0.16
  • 52 Week High
  • ADVM $10.14
  • FAAS $7.25
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 44.99
  • FAAS 49.36
  • Support Level
  • ADVM $2.27
  • FAAS $0.50
  • Resistance Level
  • ADVM $2.60
  • FAAS $0.65
  • Average True Range (ATR)
  • ADVM 0.22
  • FAAS 0.11
  • MACD
  • ADVM 0.01
  • FAAS -0.03
  • Stochastic Oscillator
  • ADVM 22.40
  • FAAS 24.10

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: